Arthur Tzianabos
Directeur/Membre du Conseil chez STOKE THERAPEUTICS, INC.
Fortune : 646 451 $ au 31/05/2024
Profil
Dr. Arthur O.
Tzianabos is a Venture Partner at 5AM Venture Management LLC, an Independent Director at Stoke Therapeutics, Inc. and a Member-Development Board at University of New Hampshire.
He is on the Board of Directors at Alliance for Regenerative Medicine, Stoke Therapeutics, Inc., Oxford Biomedica Solutions LLC and Q32 Bio, Inc. Dr. Tzianabos was previously employed as a Chairman by Akouos, Inc., a Chairman by Homology Medicines, Inc., a President & Chief Scientific Officer by OvaScience, Inc., a Senior VP, Head-Research & Early Development by Shire Plc, an Associate Professor & Member by Harvard Medical School, and a Senior VP, Head-Research & Early Development by Shire Pharmaceuticals, Inc. He also served on the board at BIND Therapeutics, Inc. and ArmaGen, Inc. He received his undergraduate degree from Boston College and a doctorate degree from the University of New Hampshire.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
STOKE THERAPEUTICS, INC.
0,06% | 31/03/2024 | 31 739 ( 0,06% ) | 464 024 $ | 31/05/2024 |
0,06% | 25/03/2024 | 7 154 ( 0,06% ) | 182 427 $ | 31/05/2024 |
Postes actifs de Arthur Tzianabos
| Sociétés | Poste | Début |
|---|---|---|
| STOKE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 17/09/2018 |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Directeur/Membre du Conseil | 03/10/2018 |
| University of New Hampshire | Corporate Officer/Principal | - |
Oxford Biomedica Solutions LLC
 Oxford Biomedica Solutions LLC Industrial MachineryProducer Manufacturing Oxford Biomedica Solutions LLC is a development partner that offers a plug and play platform for partners to achieve high titer and high product quality vector. The platform has already been proven with six separate new product inds and ctas. The American company's approach to AAV manufacturing is through continuous innovation to ensure they are delivering the highest product quality and efficacy to patients. The CEO of the joint venture company is Timothy P. Kelly. | Directeur/Membre du Conseil | - |
5AM Venture Management LLC
 5AM Venture Management LLC Investment ManagersFinance 5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US. | Private Equity Investor | 01/09/2022 |
Anciens postes connus de Arthur Tzianabos
| Sociétés | Poste | Fin |
|---|---|---|
| AKOUOS | Président | 01/12/2022 |
| DNIB UNWIND INC | Directeur/Membre du Conseil | 27/07/2016 |
OvaScience, Inc.
 OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | President | 31/03/2016 |
| SHIRE | Directeur Technique/Scientifique/R&D | 01/09/2013 |
| ░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Arthur Tzianabos
| Boston College | Undergraduate Degree |
| University of New Hampshire | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| STOKE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Health Technology |
DNIB Unwind, Inc.
 DNIB Unwind, Inc. BiotechnologyHealth Technology DNIB Unwind, Inc. develops biopharmaceutical preparations. The company was founded by Omid C. Farokhzad and Robert S. Langer on May 19, 2006 and is headquartered in Los Angeles, CA. | Health Technology |
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Akouos, Inc.
 Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. | Health Technology |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Oxford Biomedica Solutions LLC
Oxford Biomedica Solutions LLC Industrial MachineryProducer Manufacturing Oxford Biomedica Solutions LLC is a development partner that offers a plug and play platform for partners to achieve high titer and high product quality vector. The platform has already been proven with six separate new product inds and ctas. The American company's approach to AAV manufacturing is through continuous innovation to ensure they are delivering the highest product quality and efficacy to patients. The CEO of the joint venture company is Timothy P. Kelly. | Producer Manufacturing |
5AM Venture Management LLC
5AM Venture Management LLC Investment ManagersFinance 5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US. | Finance |
